Merck To Focus Taranabant Development On Lower Dose
This article was originally published in The Pink Sheet Daily
Executive Summary
Cannabinoid-1 receptor blocker shows weight loss benefits with lower adverse psychiatric events at 2 mg dose in Phase III.
You may also be interested in...
Taranabant Loss No Surprise For Obesity Field, But Shock To Merck’s Pipeline
Merck's widely expected decision to drop its Phase III obesity candidate taranabant places further doubt on the tainted cannabinoid-1 receptor antagonist class, but it also places doubt on Merck's near-term pipeline
Taranabant Loss No Surprise For Obesity Field, But Shock To Merck’s Pipeline
Merck's widely expected decision to drop its Phase III obesity candidate taranabant places further doubt on the tainted cannabinoid-1 receptor antagonist class, but it also places doubt on Merck's near-term pipeline
CB-1 Targeters For Obesity Dropping Fast
Psychiatric risk makes Merck’s taranabant the latest casualty.